BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7716842)

  • 1. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
    Pilepich MV; Krall JM; al-Sarraf M; John MJ; Doggett RL; Sause WT; Lawton CA; Abrams RA; Rotman M; Rubin P
    Urology; 1995 Apr; 45(4):616-23. PubMed ID: 7716842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Mameghan H; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; D'Este C;
    Lancet Oncol; 2005 Nov; 6(11):841-50. PubMed ID: 16257791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
    Hanks GE; Pajak TF; Porter A; Grignon D; Brereton H; Venkatesan V; Horwitz EM; Lawton C; Rosenthal SA; Sandler HM; Shipley WU;
    J Clin Oncol; 2003 Nov; 21(21):3972-8. PubMed ID: 14581419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
    Lawton CA; Winter K; Grignon D; Pilepich MV
    J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
    Lawton CAF; Lin X; Hanks GE; Lepor H; Grignon DJ; Brereton HD; Bedi M; Rosenthal SA; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Kim H; Parliament MB; Rabinovitch R; Roach M; Kwok Y; Dignam JJ; Sandler HM
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):296-303. PubMed ID: 28463149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
    Horwitz EM; Bae K; Hanks GE; Porter A; Grignon DJ; Brereton HD; Venkatesan V; Lawton CA; Rosenthal SA; Sandler HM; Shipley WU
    J Clin Oncol; 2008 May; 26(15):2497-504. PubMed ID: 18413638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
    Lawton CA; Winter K; Murray K; Machtay M; Mesic JB; Hanks GE; Coughlin CT; Pilepich MV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):937-46. PubMed ID: 11240234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
    Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
    Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
    Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
    N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
    Shipley WU; Lu JD; Pilepich MV; Heydon K; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA; Machtay M
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1302-10. PubMed ID: 12459350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
    Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
    J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
    Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
    J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
    D'Amico AV; Manola J; Loffredo M; Renshaw AA; DellaCroce A; Kantoff PW
    JAMA; 2004 Aug; 292(7):821-7. PubMed ID: 15315996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
    Corn BW; Winter K; Pilepich MV
    Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.